Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 OCT 5 ... Patients with advanced non-small cell lung cancer who are given cetuximab (Erbitux) in addition to chemotherapy are 13% less likely to die than those who receive ...
2009 AUG 17 ... decision to put KRAS on the label of two targeted drugs, Vectibix (panitumumab) and Erbitux (cetuximab). On July 17, 2009, the FDA noted that, "retrospective analyses of ...
2009 NOV 2 ... grew worldwide 36% and 30%, respectively as compared to the same period in 2008. ERBITUX® sales were down 3% compared to the third quarter 2008. ONGLYZA® has been ...
2009 AUG 17 ... on this class of drugs known as anti-EGFR monoclonal antibodies, specifically cetuximab (Erbitux®) and panitumumab (Vectibix®) have just been changed so that they will no ...
2009 OCT 5 ... According to a recent retrospective analysis of the pivotal Phase 3 CRYSTAL study, ERBITUX® (cetuximab), when added to FOLFIRI, was shown to increase median overall survival ...
2009 AUG 24 ... branch of CBER at the FDA where he was involved in the review of Avastin® and Erbitux®, the monoclonal antibodies combined with Imprime PGG in Biothera's Phase II ...
2009 AUG 17 ... the International Association for the Study of Lung Cancer. Both cetuximab (Erbitux) and erlotinib (Tarceva) inhibit the epidermal growth factor receptor (EGFR) and the ...
2009 AUG 17 ... information system for managing chemotherapy. "New drugs, like Avastin and Erbitux, are boosting survival rates nearly 100 percent from a decade ago - along with a ...
2009 OCT 12 ... Tarceva® and Avastin® in non-small cell lung cancer and in combination with Erbitux® and a Camptosar®-containing regimen in colorectal cancer," said Alice Bexon, ...
2009 AUG 17 ... of the combination. Phase 1b Clinical Trial of IMO-2055 in Combination with Erbitux® and Camptosar® in Colorectal Cancer Patient recruitment is ...
2009 AUG 3 ... Drug Administration (FDA) has approved revisions to the U.S. prescribing information for ERBITUX® (cetuximab) concerning the treatment of patients with epidermal growth factor ...
2009 OCT 12 ... trial in colorectal cancer patients. In arm one, the combination of Imprime PGG, Erbitux® (Cetuximab) and Camptosar® (Irinotecan) nearly doubled the overall response ...
2009 OCT 12 ... the success of new targeted therapies such as Herceptin, Avastin, Glivec, Nexavar and Erbitux. Underpinning that success have been real improvements in therapeutic ...
2009 OCT 19 ... According to recent research published in the journal Oncology Reports, "Cetuximab (Erbitux) has been highlighted for its anti-proliferative effects in solid tumors and it is ...
2009 SEP 7 ... Anti-epidermal growth factor receptor (EGFR) antibodies cetuximab (Erbitux) and panitumumab (Vectibix) are both targeted monoclonal antibody treatments that have ...
2009 NOV 23 ... Avastin is used predominantly in the US in the first-line setting Erbitux is indicated for use in patients with wild-type KRAS status Vectibix has ...
2009 SEP 14 ... from City of Hope and the Kimmel Cancer at Jefferson. Cetuximab (Erbitux) is a monoclonal antibody that binds to and inhibits the epidermal growth factor ...
2009 OCT 12 ... FLIRI (5-FU + leucovorin + irinotecan)], two biologically targeted drugs (avastin and erbitux), and two hydroxamic acid derivatives (vorinostat, SAHA ®, and a novel candidate, ...
2009 OCT 12 ... medical need. Within neuroscience, Abilify continues to sell well, whilst in oncology, Erbitux has been launched and is being investigated in a variety of oncology conditions. This ...
